| Metric | FY 2026 | FY 2025 |
|---|---|---|
| Revenue | 0.9 | 0.9 |
| Profit before tax | -28.0 | -33.2 |
| Net income | -29.6 | -30.5 |
| EPS (diluted, $ a share) | $-0.58 | $-1.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -4.7% |
|---|
10-K filed with the SEC, NYSE: RFL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rafael Holdings, Inc.: key numbers
- Share price
- $0.9701Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rafael Holdings, Inc.
All →Rafael Holdings Investor Presentation
Rafael Holdings filed a formal investor presentation deck (Exhibit 99.1) following its October 2026 NDA submission for remibetadex. The presentation highlights topline Phase 3 data in Niemann-Pick Disease Type C (NPC), including a prespecified analysis showing a 71% relative slowing of disease progression in a specific patient subgroup.
Rafael Holdings Financial Results
Rafael Holdings reported its fourth quarter and full fiscal year 2026 results, highlighted by a net loss of $29.6 million for the year. The company also announced that its subsidiary, Cyclo Therapeutics, submitted a New Drug Application to the FDA for remibetadex to treat Niemann-Pick Disease Type C.
- Term
- FY2026
Rafael Holdings Clinical Trial Data
Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C. While the study did not achieve statistical significance on the primary endpoint in the overall population, a prespecified analysis of patients on background therapy (83% of the study) showed a statistically significant slowing of disease progression. The company remains on track to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2026.
- Counterparty
- Cyclo Therapeutics, LLC
- Term
- 96 weeks
- Earnings call
- Sep 30, 2026, 8:30 AM ET